Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 30, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

July 29, 2026

Conditions
SarcoidosisPrecapillary Pulmonary HypertensionInterstitial Lung Disease
Interventions
DRUG

Inhaled Treprostinil

"Inhaled treprostinil causes dilatation of the pulmonary arteries and may help reduce the pulmonary pressures in this studied population.~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated."

Trial Locations (1)

32610

RECRUITING

University of Florida, Division of Pulmonary and Critical Care Medicine, Gainesville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

United Therapeutics

INDUSTRY

lead

University of Florida

OTHER

NCT03814317 - Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension | Biotech Hunter | Biotech Hunter